HCPLive Network

ACR/ARHP 2012 Annual Meeting | ACR/ARHP 2012

The 2012 ACR/ARHP Annual Meeting will present the latest evidence-based research, news, information, and educational sessions designed to "enhance practice performance and improve the quality of care in those with or at risk for arthritis and rheumatic and musculoskeletal diseases." The educational activities and other sessions at the meeting will provide practicing rheumatology professionals with expert insight and information that will identify recent developments in the diagnosis and management of patients with rheumatic diseases, explore new technologies for the treatment of rheumatologic problems, describe potential challenges in the delivery of care to patients with rheumatic diseases and specify possible solutions, present new research data to improve the quality of care of patients with rheumatic diseases, and summarize recent rheumatology research findings.
ACR/ARHP 2012 - Day 2
Overweight women face a higher risk of rheumatoid arthritis than their normal-weight peers, according to a study presented at the annual scientific meeting of the American College of Rheumatology in Washington, DC.
Although many patients suffering with low back pain are initially focused on pain relief, convincing them to shift their focus to prevention and functional improvement can lead to better clinical outcomes and greater patient satisfaction.
Claims-based analysis using powerful algorithms, predictive sampling by aggressive ZPICs, a focus on disguised kickbacks, prepayment reviews that effectively freeze billing, and other anti-fraud measures add up to a challenging regulatory environment for rheumatologists.
ACR/ARHP 2012 - Day 1
The osteoporosis therapeutic strontium ranelate reduces radiographic and radiological progression of knee osteoarthritis, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 10 to 14 in Washington, D.C.
Patients with Complex Regional Pain Syndrome (CRPS) may be afraid to volunteer information that helps clinicians accurately diagnose them.
Results presented at the American College of Rheumatology/Association of Rheumatology Professionals 2012 annual meeting show that adalimumab and methotrexate are more effective than DMARDs and prednisone in achieving remission in patients with early rheumatoid arthritis or undifferentiated arthritis patients.
Forty percent of patients treated with the uricase drug pegloticase saw complete resolution of one or more gouty tophi within 25 weeks.
Depression and increased depressive symptoms correlate with increased mortality among patients with rheumatoid arthritis, particularly men, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 10 to 14 in Washington, D.C.
$AD300x250BB$